The August 2026 recall showcases five incredible interviews highlighting recent advances in headache medicine. The episode begins with Dr. Patricia Pozo-Rosich discussing the latest advancements in headache medicine, focusing on key research findings from 2025. The episode continues with Dr. Jennifer Robblee discussing the latest consensus on refractory migraine. In the third episode of this series, Dr. Michael Eller discusses the implications of CGRP therapies in migraine treatment. The recall concludes with a two-part discussion featuring Drs. Tesha Monteith and Peter Goadsby, who highlight major developments in headache medicine presented at the 2026 AAN Annual Meeting. Podcast links: The Best of Headache Medicine from 2025: A Year in Review Refractory Headache Disorders, New Consensus, and Emergency Department Migraine Guidelines CGRP-Targeted Migraine Therapies in Patients With Vascular Risk Factors or Stroke Headache Medicine Highlights from the 2026 AAN Annual Meeting - Part 1 Headache Medicine Highlights from the 2026 AAN Annual Meeting - Part 2 Article links: Reaching International Consensus on the Definition of Refractory Migraine Using the Delphi Method 2025 Guideline Update to Acute Treatment of Migraine for Adults in the Emergency Department CGRP-Targeted Migraine Therapies in Patients With Vascular Risk Factors or Stroke Disclosures can be found at Neurology.org.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related